|
|
 |
| |
| Home > Innovative
Products |
| |
|
|
| |
TRT
Advantage:
- Stem Cell
Therapy: Development of
HUCPVC Therapy, a
source of non-embryonic stem cells for future
patient care
- Stem Cell
Banking: HUCPVC Storage for the
long-term storage of patient Umbilical Cord
Tissue stem cells collected after the full term
birth of your child
- Bone Augmentation:
Assisting the natural renewal
and remodeling of bone with OsteoScaf, our macroporous
biodegradable scaffold
| |
| |
| TRT is applying technical and working
knowledge of our rich source of stem cells and
synthetic scaffold material to advance clinical
treatments within the medical community. These
technologies are commercialized through various
established corporations through product and
technology licensing agreements. |
| |
| HUCPVC Therapy focuses on a
highly proliferating source of Mesenchymal
Stromal Cells (MSCs) isolated from human
umbilical cord. These cells function to create
and restore bone, cartilage, fat, muscle,
tendon, and ligament in the human body. MSCs
control autoimmune and inflammatory
diseases. |
| |
| HUCPVC Storage centers on
the banking of the HUCPVCs after the collection
of the baby's umbilical cord after birth. This
service is provided directly by the
licensees | |
|
 | |
of TRT technology for the future
potential clinical use of these stem cells. Companies
that offer this service under exclusive license are
CReATe Cord Blood Bank in Canada and
FutureMed Ltd. in the Middle
East. |
| |
| Our OsteoScaf scaffold
is a unique, fully resorbable 3-phase biomaterial for
application and use as a trabecular bone graft. The
scaffold aids the natural bone development of broken
bone. These characteristics make the
OsteoScaf polymeric system exclusive in
the field. OsteoScaf will be a commercial product in
2009 through our joint venture company Skeleton
Regeneration Ltd. in San Antonio, Texas. |
| |
| The HUCPVC Therapy
partnered with the OsteoScaf reveals a
very interesting proposition for TRT. By marrying both
TRT technologies not only does one compliment the other
by allowing HUCPVC stem cells to aid the scaffold with
bone growth but it leaves a wealth of opportunities for
research and development. |
| | |
| |
